MedTrace Logo

Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens

NCT00886990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2020-07-17

No results posted yet for this study

Summary

The virological efficacy will be no different in children treated with single versus double boosted PI second line ART regimens.

Conditions

  • HIV Infection
  • HIV Infections

Interventions

DRUG

ritonavir-boosted PI-based second line treatments

single PI boosted by low dose ritonavir

DRUG

two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir

two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir

Sponsors & Collaborators

  • Ministry of Education, Thailand

    collaborator OTHER

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Thanyawee Puthanakit, MD · The HIV Netherlands Australia Thailand Research Collaboration

  • Jintanat Ananworanich, MD, Ph.D · The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) and South East Asia Research Collaboration with Hawaii (SEARCH), The Thai Red Cross AIDS Research Centre, Bangkok

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886990 on ClinicalTrials.gov